VanEck Biotech ETF (NASDAQ:BBH) vs. BlackRock MuniYield New York Quality Fund (NYSE:MYN) Critical Survey

VanEck Biotech ETF (NASDAQ:BBH) and BlackRock MuniYield New York Quality Fund (NYSE:MYN) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Profitability

This table compares VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VanEck Biotech ETF	N/A	N/A	N/A
BlackRock MuniYield New York Quality Fund	N/A	N/A	N/A

Volatility and Risk

VanEck Biotech ETF has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, BlackRock MuniYield New York Quality Fund has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Dividends

VanEck Biotech ETF pays an annual dividend of $1.25 per share and has a dividend yield of 0.8%. BlackRock MuniYield New York Quality Fund pays an annual dividend of $0.54 per share and has a dividend yield of 5.3%.

Valuation & Earnings

This table compares VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VanEck Biotech ETF	N/A	N/A	N/A	N/A	N/A
BlackRock MuniYield New York Quality Fund	$19.20 million	20.31	N/A	N/A	N/A

Institutional and Insider Ownership

32.0% of VanEck Biotech ETF shares are held by institutional investors. Comparatively, 29.3% of BlackRock MuniYield New York Quality Fund shares are held by institutional investors. 1.0% of BlackRock MuniYield New York Quality Fund shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for VanEck Biotech ETF and BlackRock MuniYield New York Quality Fund, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VanEck Biotech ETF	0	4	2	0	2.65
BlackRock MuniYield New York Quality Fund	0	0	0	0	0.00

VanEck Biotech ETF currently has a consensus price target of $160.63, suggesting a potential upside of 0.00%. Given VanEck Biotech ETF’s stronger consensus rating and higher probable upside, equities research analysts plainly believe VanEck Biotech ETF is more favorable than BlackRock MuniYield New York Quality Fund.

Summary

VanEck Biotech ETF beats BlackRock MuniYield New York Quality Fund on 5 of the 8 factors compared between the two stocks.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

About BlackRock MuniYield New York Quality Fund

BlackRock MuniYield New York Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in a portfolio of long-term investment grade municipal bonds exempt from federal income taxes and New York State and New York City personal income taxes. BlackRock MuniYield New York Quality Fund, Inc was formed on March 16, 1992 and is domiciled in United States.